China Shenghuo Pharmaceutical Retains Grayling Global As Investor Relations Counsel

Thursday, July 24, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

KUNMING, China, July 24 China ShenghuoPharmaceutical Holdings, Inc. (Amex: KUN) ("China Shenghuo" or "the Company"),which is engaged in the research, development, manufacture, and marketing ofpharmaceutical, nutritional supplement and cosmetic products in the People'sRepublic of China ("PRC"), today announced that it has retained GraylingGlobal to lead a strategic communications program (''the IR program'') toshareholders, the investment community and financial media.

"Grayling Global was selected to represent China Shenghuo after a thoroughreview of numerous candidates,'' said Mr. Guihua Lan, the Chairman and CEO ofChina Shenghuo. ''The firm's longstanding investor relations track record inthe healthcare sector, its keen understanding of the Chinese marketplace andits strong ability to enhance shareholder value for clients were the keyreasons we selected them to assist us in our investor relations efforts. Webelieve Grayling's effective communications programs and impressive reputationof developing long-term relationships with the investment community willenable China Shenghuo to generate investor awareness and visibility.''

Grayling Global, a subsidiary of Huntsworth PLC (LSE: HNT), isheadquartered in London, with offices in New York, Brussels, Bangkok,Singapore, Madrid, Moscow, Tel Aviv, Shanghai, Istanbul, Los Angeles,Sacramento, Dublin, Edinburgh, Cardiff, Bristol, and Birmingham. The firm hasover 200 consultants, focusing on first-class delivery in public affairs,public relations, investor relations and events management.

About China Shenghuo

Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("ChinaShenghuo" or "the "Company") is a specialty pharmaceutical company thatfocuses on the research, development, production and marketing of Sanchi-basedmedicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical(Group) Co., Ltd. ("Kunming Shenghuo"), it owns thirty SFDA (State Food andDrug Administration) approved medicines, including the flagship productXuesaitong Soft Capsules, which has already been listed in the InsuranceCatalogue. At present, China Shenghuo incorporates a sales network of agenciesand representatives throughout China, which markets Sanchi-based traditionalChinese medicine to hospitals and drug stores as prescription and OTC drugsprimarily for the treatment of cardiovascular, cerebrovascular and pepticulcer disease. The Company also exports medicinal products to Asian countriessuch as Indonesia, Russia and Kyrgyzstan. For more information, please visit .

Forward Looking Statements

This press release may contain certain "forward-looking statements," asdefined in the United States Private Securities Litigation Reform Act of 1995,that involve a number of risks and uncertainties. There can be no assurancethat such statements will prove to be accurate and the actual results andfuture events could differ materially from management s current expectations.Such factors include, but are not limited to, the Company s reliance on onesupplier for Sanchi, ability to develop and market new products, ability toestablish and maintain a strong brand, continued maintenance of certificates,permits and licenses required to conduct business in China, protection ofcompany's intellectual property rights, market acceptance of the company sproducts, changes in the laws of the People s Republic of China that affectthe company s operations, the company s ability to obtain all necessarygovernment certifications and/or licenses to open and operate retail specialtycounters to offer its cosmetic products and conduct the company s business,cost of complying with current and future governmental regulations and theimpact of any changes in the regulations on the Company's operations and otherfactors detailed from time to time in the Company's filings with the UnitedStates Securities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store